Inclusion body myositis triggerred with long-term imatinib use.

Autor:	Deniz R; Department of Rheumatology, University of Health Sciences Başakşehir Çam and Sakura City Hospital, Istanbul, Turkey.; Department of Internal Medicine, Istanbul University Faculty of Medicine, Istanbul, Turkey., Güzelbey T; Department of Radiology, University of Health Sciences Başakşehir Çam and Sakura City Hospital, Istanbul, Turkey., Narinoğlu S; Department of Internal Medicine, University of Health Sciences Başakşehir Çam and Sakura City Hospital, Istanbul, Turkey., Şirin Kalem G; Department of Internal Medicine, University of Health Sciences Başakşehir Çam and Sakura City Hospital, Istanbul, Turkey., Ekmen ŞA; Department of Internal Medicine, University of Health Sciences Başakşehir Çam and Sakura City Hospital, Istanbul, Turkey., Gündoğdu Ünverengil G; Department of Pathology, Istanbul University Faculty of Medicine, Istanbul, Turkey., Karaali Z; Department of Internal Medicine, University of Health Sciences Başakşehir Çam and Sakura City Hospital, Istanbul, Turkey.
Jazyk:	angličtina
Zdroj:	Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners [J Oncol Pharm Pract] 2024 Dec; Vol. 30 (8), pp. 1460-1464. Date of Electronic Publication: 2023 Apr 10.
DOI:	10.1177/10781552231168563
Abstrakt:	Introduction: Imatinib is an orally administered tyrosine kinase inhibitor with wide clinical use in different indications from solid tumors to hematologic malignancies. Inclusion body myositis (IBM) is an acquired myopathy of both inflammatory and degenerative nature. Case Report: We present an 81 years old male with a history of gastrointestinal stromal tumor (GIST) operated 8 years ago and was evaluated for the progressive loss of weight and muscle strength leading to total immobilization in 6 months. He was under imatinib for 8 years despite the remission of GIST. Physical examination disclosed diffuse loss of muscle strength, most prominently involvement of distal upper and proximal lower extremity in an asymmetrical pattern with normal serum creatinine kinase level (CK). Further investigations including bilateral thigh MRI, electromyography (EMG), and PET/CT suggested myositis and degenerative myopathy and ruled out any malignancy. Quadriceps femoris biopsy proved the diagnosis of IBM and no trigger except for imatinib was displayed. Management and Outcome: Clinical improvement in terms of weight loss and muscle weakness was achieved after the discontinuation of imatinib. Discussion: This is the first case of IBM associated with prolonged use of imatinib not reported in the literature so far. Since imatinib is widely used in different conditions, it is important to be aware of even its rare adverse effects. Poor response of IBM to conventional immunosuppressive agents enhances the value of etiology identification to relieve symptoms in addition to supportive care. Competing Interests: Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu